Caribou Biosciences, one of the first companies founded to advance CRISPR gene editing in medicine, announced October 6 that it is discontinuing research, laying off staff, and seeking strategic alternatives. The board will consider mergers, acquisitions, or other transactions for the company or its assets, and the “substantial reduction in workforce” will be mostly complete by the end of the year.
The decision ends work on two off-the-shelf CAR-T cancer therapies, including vispa-cel, which was ready for Phase 3 testing with an FDA-agreed trial design. CEO Rachel Haurwitz said the financing environment for allogeneic CAR-T made it “increasingly challenging to secure the capital necessary to responsibly advance these programs.” Leerink Partners analyst Daina Graybosch wrote that investors were unwilling to fund the trial with questions lingering about clinical risk, the company’s HLA-matching strategy, and the strength of vispa-cel’s data.
Caribou began operations in 2011 with co-founders including Jennifer Doudna, the Nobel laureate for CRISPR work, and went public in 2021 in one of the field’s biggest IPOs. Its shares briefly topped $30 in September 2021 and now trade under $1. A disappointing vispa-cel readout in June 2024, a 12 percent workforce cut the next month, and a 2025 retreat from autoimmune work preceded this week’s decision. The arc illustrates the sector’s core problem: off-the-shelf allogeneic therapies promise cheaper, faster cell therapy than personalized CAR-T, but research setbacks and durability questions have dried up the capital needed to prove it.
The next chapter is now about the shell, not the science. BioPharma Dive reported October 8 that Caribou’s board has authorized management to evaluate a merger, acquisition or business combination and tapped Wedbush Securities as its exclusive financial advisor. With roughly $114 million in cash, cash equivalents and marketable securities at the end of the second quarter, Caribou carries a negative enterprise value of about $20 million to $30 million, meaning the market values the operating business at less than nothing. Deal experts told the outlet that a company publicly exploring strategic alternatives is “low-hanging fruit” for reverse mergers, of which roughly two dozen have been announced in biotech this year. Leerink analyst Daina Graybosch sees the natural endpoint as a reverse merger or a buyout by Tang Capital, the San Diego firm known for acquiring cash-rich biotechs. Whether the discontinued vispa-cel program finds a new home is doubtful: Graybosch said rival allogeneic programs at Fate Therapeutics and AvenCell Therapeutics make it hard to justify wrapping a new company around Caribou’s asset.